Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by pennyDoctoron Dec 09, 2019 4:59pm

135 Views

Post# 30437390

RE:Patent Update

++ Chemical

Takes a long time to get the patent... Filed in 2015 and updated in 2019 still in process.
https://patentimages.storage.googleapis.com/d7/85/86/a6593232601535/CA2942731A1.pdf

The document for Canada and World Protection of Intellectual Property is a very detailed 130 page document to patent the process for Glycopeptide prepartion using Flourination. The current share price does not take into account the value of this eventual patent and Wolikombi might be closer to the value with $4.30.

WiITHOUT the patent for anti aging I am sure the value would be over a dollar before phase 2 clinical trials for SGL2.

Sooooo Excited!!!!!

Bullboard Posts

Corus reports Q1 profit drop in the face of falling revenue